Hope et al. [76] reported first in human experience that AR inhibition increases PSMA expression in prostate cancer metastases and increases the number of lesions visualized on PSMA-based positron emission tomography (PET) imaging. This evidence concerns the gene FOLH1 and prostate carcinoma.